Home » Newsletters » BioWorld Science

BioWorld Science

April 21, 2017

View Archived Issues

First-described mouse model for moyamoya disease

Atossa Genetics receives positive interim review of phase I endoxifen trial

uniQure decides not to seek marketing authorization renewal for Glybera in Europe

A novel live-attenuated Zika virus vaccine demonstrates promising safety and efficacy in mice

First patient treated in phase II trial of OXS-1550

Novel SERD G1T48 shows preclinical efficacy for breast cancer

PTC Therapeutics completes acquisition of U.S. rights to Emflaza for Duchenne muscular dystrophy

FDA issues complete response letter for CCP-07

Cyclophilin inhibitor NV-556 shows preclinical promise for liver fibrosis in NASH

New ER stress inhibitors as probe compounds to investigate treatments for neurodegenerative diseases

Jounce begins phase II portion of ICONIC trial of JTX-2011

Phase III GLOBE study of VB-111 in recurrent GBM recommended to continue

FDA grants orphan drug designation to Efranat's EF-022

EMA renders negative trend vote on XBiotech's MAA for colorectal cancer candidate antibody

ReNeuron updates progress of stroke disability and retinal disease programs

BMS-986158 shows promise for cancer treatment

Galileo Research's non-restricted T-cell line receives orphan drug designation

Saniona achieves second Parkinson's milestone under Michael J. Fox Foundation grant

Nissan Chemical and Shionogi form analgesic research collaboration

Pierre Fabre Medicament and CNRS present DNMT1 and DNMT3 inhibitors

Grail initiates STRIVE study to validate blood test to detect breast cancer

FDA grants orphan drug status to Lonsurf for the treatment of gastric cancer

Quartet Medicine and EPFL patent SPR inhibitors

Selvita SA divulges LDHA and LDHB inhibitors

Japanese approval sought for guselkumab

Basilea reaches SPA agreement with FDA on phase III studies of ceftobiprole

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...